Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:52:36 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:OCUL - OCULAR THERAPEUTIX INC - http://www.ocutx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
OCUL - Q0.15.89·6.440.15.868.54913    11.31  1.99508:23:03Apr 1815 min RT 2¢

Recent Trades - Last 10 of 13
Time ETExPriceChangeVolume
08:23:03Q5.950.096
08:00:05Q5.930.0750
08:00:04Q6.000.1450
08:00:03Q5.84-0.02200
08:00:01Q5.910.052,100
08:00:01Q5.920.0613
08:00:00Q5.920.0616
08:00:00Q5.920.065
08:00:00Q6.010.159
07:53:48Q5.920.06552

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 07:00U:OCULNews ReleaseOcular Therapeutix(TM) Announces Positive Topline Phase 1 Data for AXPAXLI(TM) in Diabetic Retinopathy
2024-04-16 07:00U:OCULNews ReleaseOcular Therapeutix(TM) Strengthens Clinical Team with Appointment of Key Retinal Leaders
2024-04-15 07:00U:OCULNews ReleaseOcular Therapeutix(TM) Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
2024-04-09 07:30U:OCULNews ReleaseOcular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
2024-04-06 10:00U:OCULNews ReleaseOcular Therapeutix(TM) Announces Positive Phase 2 PAXTRAVA(TM) Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
2024-03-26 07:30U:OCULNews ReleaseOcular Therapeutix(TM) To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
2024-03-11 16:05U:OCULNews ReleaseOcular Therapeutix(TM) Reports Fourth Quarter and Full Year 2023 Results
2024-03-05 07:30U:OCULNews ReleaseOcular Therapeutix(TM) to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
2024-02-22 07:32U:OCULNews ReleaseOcular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
2024-02-22 07:31U:OCULNews ReleaseOcular Therapeutix, Inc. Announces $325.0 Million Private Placement
2024-02-22 07:30U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Announces Board of Directors and Leadership Updates
2024-02-19 09:00U:OCULNews ReleaseAffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA ‚ ® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctiv
2024-02-15 08:00U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Appoints Steve Meyers to Chief Commercial Officer
2024-02-13 07:38U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI ¢ „ ¢ in Wet AMD
2024-01-25 08:00U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI ¢ „ ¢ in Wet AMD
2023-12-18 16:01U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
2023-12-13 22:10U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Announces Pricing of Public Offering of Common Stock
2023-12-13 16:01U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Announces Proposed Public Offering of Common Stock
2023-11-08 08:00U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ to Present at Three Upcoming Investor Conferences
2023-11-07 16:01U:OCULNews ReleaseOcular Therapeutix ¢ „ ¢ Provides Third Quarter 2023 Financial Results and Corporate Update